Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 20;23(20):12604.
doi: 10.3390/ijms232012604.

Non-Traditional Pro-Inflammatory and Pro-Atherosclerotic Risk Factors Related to Systemic Lupus Erythematosus

Patricia Richter  1   2 , Anca Cardoneanu  1   2 , Ciprian Rezus  3   4 , Alexandra Maria Burlui  1   2 , Elena Rezus  1   2
Affiliations
Review

Non-Traditional Pro-Inflammatory and Pro-Atherosclerotic Risk Factors Related to Systemic Lupus Erythematosus

Patricia Richter et al. Int J Mol Sci. .

Abstract

Cardiovascular diseases (CVD) are one of the leading causes of high mortality in patients with systemic lupus erythematosus (SLE). The Framingham risk score and other traditional risk factors do not fully reflect the CVD risk in SLE patients. Therefore, in order to stratify these high-risk patients, additional biomarkers for subclinical CVD are needed. The mechanisms of atherogenesis in SLE are still being investigated. During the past decades, many reports recognized that inflammation plays a crucial role in the development of atherosclerosis. The aim of this report is to present novel proinflammatory and pro-atherosclerotic risk factors that are closely related to SLE inflammation and which determine an increased risk for the occurrence of early cardiovascular events.

Keywords: atherosclerosis; cytokines; inflammation; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Stages of atherosclerosis mechanism in SLE patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hammad S.M., Harden O.C., Wilson D.A., Twal W.O., Nietert P.J., Oates J.C. Plasma Sphingolipid Profile Associated With Subclinical Atherosclerosis and Clinical Disease Markers of Systemic Lupus Erythematosus: Potential Predictive Value. Front. Immunol. 2021;12:694318. doi: 10.3389/fimmu.2021.694318. - DOI - PMC - PubMed
    1. Teixeira V., Tam L.S. Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. Front. Med. 2018;4:262. doi: 10.3389/fmed.2017.00262. - DOI - PMC - PubMed
    1. Leone P., Cicco S., Prete M., Solimando A.G., Susca N., Crudele L., Buonavoglia A., Colonna P., Dammacco F., Vacca A., et al. Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease. Clin. Exp. Med. 2020;20:11–19. doi: 10.1007/s10238-019-00600-8. - DOI - PubMed
    1. Lorenzo-Vizcaya A., Isenberg D. Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom. Lupus. 2021;30:702–706. doi: 10.1177/0961203320988607. - DOI - PubMed
    1. Ståhl-Hallengren C., Jönsen A., Nived O., Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: Increasing age, decreasing frequency of renal manifestations and good prognosis. J. Rheumatol. 2000;27:685–691. - PubMed